[Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis].
Fifty-six patients with recurrent bronchopulmonary infections associated with chronic bronchitis were randomly allocated to 2 groups, to assess whether treatment with an immunomodulator, Diribiotin CK, could enhance resistance to infection. The double-blind, placebo-controlled prospective trial over a 9 month period showed that this immunomodulator was well tolerated and significantly reduced the rate of respiratory tract infection. The drug also significantly reduced the prescribing of antibiotic medication and the rate of absenteism from work. These effects have been demonstrated in a rigorously designed clinical study. This is the first time that a clear clinical activity has been attributed to an inducer of soluble mediators of immunity.
Rochemaure
J
J
Hôtel-Dieu de Paris.
Lehert
P
P
Sauvaget
J
J
Robillard
M
M
Betbeder-Matibet
A
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000150:complications*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007709:Klebsiella; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000150:complications / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D010919:Placebos
Réduction par un immunomodulateur du taux d'infections respiratoires dans la bronchite chronique.